Trials / Completed
CompletedNCT00171587
Study of the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
A Phase IB, Open-label, Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety, tolerability, dose limiting toxicity, and maximum tolerated dose of vatalanib administered orally once daily in combination with capecitabine in patients with advanced cancer. The study is also designed to determine the effect of vatalanib on the pharmacokinetics of capecitabine and the effect of capecitabine on the pharmacokinetics of vatalanib, and to describe the anti-tumor activity of this combination regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PTK787/ZK 222584 (vatalanib) |
Timeline
- Start date
- 2002-05-01
- Primary completion
- 2007-03-01
- Completion
- 2007-03-01
- First posted
- 2005-09-15
- Last updated
- 2009-11-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00171587. Inclusion in this directory is not an endorsement.